ICON Sets Financial Forecast for 2024 Full Year
ICON plc, a global clinical research organization, has projected financial targets for the year ending December 31, 2024. The...
Innovative Merck-Inspirna Deal: New Hope in Cancer Battle
Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc., New York, for the development of...
Revolutionary J-Brain Cargo® Tech in JCR Alexion Deal
JCR Pharmaceuticals Co., Ltd. has entered into a Research Collaboration, Option, and License Agreement with Alexion, AstraZeneca Rare Disease,...
China’s Bold Takeda Choice: LIVTENCITY’s Unique Edge
Takeda has announced the approval of LIVTENCITY® (maribavir) by the National Medical Products Administration (NMPA) of China for treating...
AstraZeneca & Daiichi Breakthrough Trial: New Breast Cancer Therapy Tested
Daiichi Sankyo and AstraZeneca have begun dosing the first patient in two global, randomized Phase 3 trials of their...
Gilead’s $848M Bet on Compugen’s Revolutionary Therapy
Gilead Sciences, Inc. has entered into an agreement with Israeli company Compugen Ltd., a clinical-stage cancer immunotherapy firm, to...
Zurzuvae: New Hope Pill for Moms with Post-Partum Depression
Sage Therapeutics, Inc. and Biogen Inc. have announced the availability of ZURZUVAE™ (zuranolone) by prescription in the United States...
FDA Nods to Padcev-Keytruda for Bladder Cancer
Pfizer Inc. and Astellas Pharma Inc. have announced the FDA’s approval of PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC])...
BMS’s RELATIVITY-123 Trial Fail: A Devastating End
Bristol Myers Squibb announced the discontinuation of the Phase 3 RELATIVITY-123 trial, which was evaluating the fixed-dose combination of...
Pfizer Seals Deal: Seagen Now Acquired for $229/Share
Pfizer Inc. has announced the completion of its acquisition of Seagen Inc., marking a significant expansion in its commitment...